Pacira BioSciences, Inc.
Rank #95HypergrowthPCRX · Nasdaq · Healthcare
Pacira BioSciences, Inc. (PCRX) — Rank #95 by gross profitability (GP/assets 0.46) · ROE 1.0% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001396814 · all metrics point-in-time as of the filing date.
About
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Show moreShow less
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc.
was incorporated in 2006 and is headquartered in Brisbane, California.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- pacira.com
Segments
A revenue-by-segment breakdown is not available for PCRX. This is expected for a single-reportable-segment filer with no product/service revenue disaggregation, or for a company whose filings predate SEC’s XBRL viewer.